WO2017209553A3 - Method for screening antibody using patient-derived cells - Google Patents

Method for screening antibody using patient-derived cells Download PDF

Info

Publication number
WO2017209553A3
WO2017209553A3 PCT/KR2017/005766 KR2017005766W WO2017209553A3 WO 2017209553 A3 WO2017209553 A3 WO 2017209553A3 KR 2017005766 W KR2017005766 W KR 2017005766W WO 2017209553 A3 WO2017209553 A3 WO 2017209553A3
Authority
WO
WIPO (PCT)
Prior art keywords
patient
derived cells
screening antibody
screening
antigen
Prior art date
Application number
PCT/KR2017/005766
Other languages
French (fr)
Korean (ko)
Other versions
WO2017209553A2 (en
Inventor
남도현
Original Assignee
사회복지법인 삼성생명공익재단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사회복지법인 삼성생명공익재단 filed Critical 사회복지법인 삼성생명공익재단
Priority to JP2018562986A priority Critical patent/JP6895460B2/en
Priority to US16/306,566 priority patent/US11199536B2/en
Priority to CN201780041974.6A priority patent/CN109416364B/en
Priority to AU2017273169A priority patent/AU2017273169B2/en
Priority to CA3026236A priority patent/CA3026236C/en
Priority to SG11201810779PA priority patent/SG11201810779PA/en
Priority to EP17807046.2A priority patent/EP3480598A4/en
Priority claimed from KR1020170069140A external-priority patent/KR101993892B1/en
Publication of WO2017209553A2 publication Critical patent/WO2017209553A2/en
Publication of WO2017209553A3 publication Critical patent/WO2017209553A3/en

Links

Abstract

The present invention relates to a method for screening an antibody or an antigen binding fragment thereof using patient-derived cells and, more particularly, to a method for screening an antibody specifically binding to an antigen or an antigen binding fragment thereof using patient-derived cells containing the antigen.
PCT/KR2017/005766 2016-06-03 2017-06-02 Method for screening antibody using patient-derived cells WO2017209553A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2018562986A JP6895460B2 (en) 2016-06-03 2017-06-02 Antibody screening method using patient-derived tumor spheroids
US16/306,566 US11199536B2 (en) 2016-06-03 2017-06-02 Method for screening antibody using patient-derived tumor spheroids
CN201780041974.6A CN109416364B (en) 2016-06-03 2017-06-02 Method for screening antibodies using patient-derived tumor spheres
AU2017273169A AU2017273169B2 (en) 2016-06-03 2017-06-02 Method for screening antibody using patient-derived tumor spheroids
CA3026236A CA3026236C (en) 2016-06-03 2017-06-02 Method for screening antibody using patient-derived tumor spheroids
SG11201810779PA SG11201810779PA (en) 2016-06-03 2017-06-02 Method for screening antibody using patient-derived tumor spheroids
EP17807046.2A EP3480598A4 (en) 2016-06-03 2017-06-02 Method for screening antibody using patient-derived cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20160069355 2016-06-03
KR10-2016-0069355 2016-06-03
KR10-2017-0069140 2017-06-02
KR1020170069140A KR101993892B1 (en) 2016-06-03 2017-06-02 Method of Screening Antibody Using Patient Derived Cell

Publications (2)

Publication Number Publication Date
WO2017209553A2 WO2017209553A2 (en) 2017-12-07
WO2017209553A3 true WO2017209553A3 (en) 2018-01-18

Family

ID=60477675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/005766 WO2017209553A2 (en) 2016-06-03 2017-06-02 Method for screening antibody using patient-derived cells

Country Status (1)

Country Link
WO (1) WO2017209553A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3115102A1 (en) 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Anti-npr1 antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020199212A1 (en) * 2001-05-10 2002-12-26 Saburo Sone Non-human animal exhibiting bone metastasis of tumor cells and method of screening for bone metastasis inhibitors
KR101096359B1 (en) * 2005-11-08 2011-12-20 제넨테크, 인크. Neuropilin Antagonists
KR20120048563A (en) * 2009-06-22 2012-05-15 번햄 인스티튜트 포 메디칼 리서치 Methods and compositions using peptides and proteins with c-terminal elements

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
ATE87659T1 (en) 1986-09-02 1993-04-15 Enzon Lab Inc BINDING MOLECULES WITH SINGLE POLYPEPTIDE CHAIN.
DE3852304T3 (en) 1987-03-02 1999-07-01 Enzon Lab Inc Organism as carrier for "Single Chain Antibody Domain (SCAD)".
DE3852074D1 (en) 1987-03-20 1994-12-15 Creative Biomolecules Inc METHOD FOR PURIFYING RECOMBINANT POLYPEPTIDES.
JP2535066B2 (en) 1987-03-20 1996-09-18 クリエイティブ・バイオマリキュールズ・インコーポレーテッド Leader sequence for recombinant protein production
JPH02500329A (en) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド Targeted multifunctional protein
WO2011143408A1 (en) 2010-05-13 2011-11-17 Genentech, Inc. Use of neuropilin-1 antagonists for the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020199212A1 (en) * 2001-05-10 2002-12-26 Saburo Sone Non-human animal exhibiting bone metastasis of tumor cells and method of screening for bone metastasis inhibitors
KR101096359B1 (en) * 2005-11-08 2011-12-20 제넨테크, 인크. Neuropilin Antagonists
KR20120048563A (en) * 2009-06-22 2012-05-15 번햄 인스티튜트 포 메디칼 리서치 Methods and compositions using peptides and proteins with c-terminal elements

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WILLIAMS ET AL.: "Identification of an Antibody Fragment Specific for Androgen-dependent Prostate Cancer Cells", BMC BIOTECHNOLOGY, vol. 4, 3 September 2014 (2014-09-03), pages 1 - 11, XP021195833 *
WILLIAMS ET AL.: "In Vitro Selection of Cancer Cell -specific Molecular Recognition Elements from Amino Acid Libraries", JOURNAL OF IMMUNOLOGY RESEARCH, vol. 2015, 7 September 2015 (2015-09-07), pages 1 - 12, XP055556675 *

Also Published As

Publication number Publication date
WO2017209553A2 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
MX2020001879A (en) Antigen-binding proteins tatrgeting shared antigens.
EP3471773A4 (en) Cd3 binding antibodies
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
EP3765522A4 (en) Anti-claudin 18.2 antibodies
EP3411071A4 (en) Novel cd47 monoclonal antibodies and uses thereof
WO2018109170A3 (en) Il-11ra antibodies
WO2016077381A8 (en) Anti-interleukin-33 antibodies and uses thereof
WO2017147542A3 (en) Optimized transglutaminase site-specific antibody conjugation
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
WO2016073789A3 (en) Anti-fgfr2/3 antibodies and methods using same
WO2017106684A3 (en) Antibodies specifically binding hla-dr and their uses
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
WO2015091853A3 (en) Human anti-cd40 human antibodies
EP4017883A4 (en) Novel anti-cldn18.2 antibodies
EP3824096A4 (en) Novel antibodies and methods for making and using the same
WO2015127136A3 (en) Ebola monoclonal antibodies
PH12019500551A1 (en) Antibody specifically binding to il-17a and functional fragment thereof
MY189618A (en) Antibody specifically binding to pd-1 and functional fragment thereof
WO2015200522A3 (en) Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species
WO2018071910A3 (en) Anti-il1-rap antibodies
WO2015075269A9 (en) Antibodies against ccr9 and applications thereof
WO2015187018A3 (en) Means and methods for determining t cell recognition
EP3692072A4 (en) Anti-hla-dq2.5 antibody
WO2018138681A9 (en) Hemagglutinin-specific antibodies and uses thereof
EP3947466A4 (en) Anti-hla-dq2.5 antibody

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17807046

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2018562986

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3026236

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017807046

Country of ref document: EP

Effective date: 20190103

ENP Entry into the national phase

Ref document number: 2017273169

Country of ref document: AU

Date of ref document: 20170602

Kind code of ref document: A